



UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FLING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
--------------------	------------	-----------------------	---------------------

EXAMINER

ART UNIT	PAPER NUMBER
----------	--------------

1804

47

DATE MAILED:

INTERVIEW SUMMARY

All participants (applicant, applicant's representative, PTO personnel):

(1) Dr. Piersbacher (3) Ex. Zedler
(2) Ms. Campbell (4) _____

Date of Interview 5/8/97

Type: ☒ Telephonic ☐ Personal (copy is given to ☐ applicant ☐ applicant's representative).

Exhibit shown or demonstration conducted: ☐ Yes ☒ No If yes, brief description: _____

Agreement ☒ was reached. ☐ was not reached. *in part, see below.*

Claim(s) discussed: all pending in general

Identification of prior art discussed: N.A.

Description of the general nature of what was agreed to if an agreement was reached, or any other comments: The amendments to the claims 21-25, cancellation of 27-29, and cancellation of other non-related claims put the claims in condition for allowance pending receipt of evidence or declaration showing steps to overcome (112C.1) rejection of novel to disease. See copy of attached claims.

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

1. ☐ It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary. A FORMAL WRITTEN RESPONSE TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a response to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

2. ☐ Since the Examiner's interview summary above (including any attachments) reflects a complete response to each of the objections, rejections and requirements that may be present in the last Office action, and since the claims are now allowable, this completed form is considered to fulfill the response requirements of the last Office action. Applicant is not relieved from providing a separate record of the interview unless box 1 above is also checked.

Examiner Note: You must sign this form unless it is an attachment to another form.

FORM PTOL-413 (REV.1-96)

Suzanne Fuba

EXHIBIT A

PENDING CLAIMS

(As of Office Action mailed February 19, 1997)

Re: United States Patent Application No. 08/349,479
Entitled: INHIBITING TRANSFORMING GROWTH FACTOR BETA TO
PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX
Inventors: Border and Ruoslahti
Filed: December 2, 1994
Our Docket: P-LA 1245

21. A method of ^{decreasing accumulation of ECM in} ~~treating~~ a pathology or a condition characterized by the TGF- β -induced production and deleterious accumulation of an extracellular matrix component in a tissue comprising:
contacting the tissue with an ~~agent that~~ ^{agent} binds to a TGF- β ;
whereby the binding of the agent to the TGF- β suppresses the deleterious accumulation of the TGF- β -induced extracellular matrix component in the tissue; ~~and~~ ^{whereby the suppression of the deleterious accumulation of the extracellular matrix component treats the pathology or condition.}
22. The method of claim 21, wherein the pathology or condition is glomerulonephritis.
23. The method of claim 21, wherein the pathology or condition is selected from the group consisting of adult respiratory distress syndrome or cirrhosis of the liver.
24. The method of claim 21, wherein the agent comprises an anti-TGF- β antibody.
25. The method of claim 24, wherein the condition is scarring.
27. A method of decreasing the deleterious accumulation of a TGF- β induced extracellular matrix component in a tissue comprising:
contacting the tissue with an agent which decreases the activity of TGF- β ; or
contacting the tissue with an agent which inhibits the extracellular matrix component-inducing activity of the TGF- β ;
whereby the decrease in the activity of the TGF- β decreases the deleterious accumulation of the extracellular matrix component; and
whereby the agent is not a general protein synthesis inhibitor.
28. The method of claim 21 or 27, wherein the cell is a mesangial cell.
- 29.